Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-? receptor agonist or an IFN-? receptor agonist, for the treatment of cancer.
Type:
Application
Filed:
May 25, 2012
Publication date:
November 13, 2014
Applicants:
The General Hospital Corporation, CytoCure LLC
Inventors:
Timothy J. Haggerty, James T. Kurnick, Ian S. Dunn
Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-? receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.
Type:
Application
Filed:
October 19, 2011
Publication date:
August 2, 2012
Applicant:
CytoCure LLC
Inventors:
Paul J. Durda, James T. Kurnick, Ian S. Dunn
Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-? receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.
Type:
Grant
Filed:
August 29, 2003
Date of Patent:
December 6, 2011
Assignee:
CytoCure LLC
Inventors:
Paul Durda, James T. Kurnick, Ian S. Dunn
© 2025 Justia
